This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 13 November 2003 (13.11.2003)

PCT

(10) International Publication Number WO 03/093222 A1

(51) International Patent Classification7: C07C 233/63, A61K 31/198

(21) International Application Number: PCT/IN02/00114

(22) International Filing Date: 29 April 2002 (29.04.2002)

(25) Filing Language:

English

(26) Publication Language:

English

- (71) Applicant (for all designated States except US): BIOCON INDIA LIMITED [IN/IN]; 20th K.M. Hosur Road, Hebbagodi, Bangalore 561 229, Karnataka (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): RAJAMAHEN-DRA, Shanmughasamy [IN/IN]; Biocon India Limited, 20th Km. Hosur Road, Hebbagodi, Bangalore 561 229, Karnataka (IN). ASWATHANARAYANAPPA, Chandrashekar [IN/IN]; Biocon India limited, 20th Km Hosur Road, Hebbagodi, Bangalore 561 229, Karnataka (IN). PUTHIAPARAMPIL, Tom, Thomas [IN/IN]; Biocon India Limited, 20th Km Hosur Road, Hebbagodi, Bangalore 561 229, Karnataka (IN). SRIDHARAN, Madhavan [IN/IN]; Biocon India Limited, 20th Km Hosur Road, Hebbagodi, Bangalore 561 229, Karnataka (IN). GANESH,

Sambasivam [IN/IN]; Biocon India Limited, 20th Km Hosur Road, Hebbagodi, Bangalore 561 229, Karnataka (IN).

- (74) Agents: ANAND, Pravin et al.; Anand & Anand Advocates, B-41, Nizamuddin East, New Delhi 110 013 (IN).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


- of inventorship (Rule 4.17(iv)) for US only

Published:

with international search report

[Continued on next page]

(54) Title: NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE



(57) Abstract: Novel polymorph Form C of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine is produced having different infra red spectrum and X-ray diffraction patterns from previously known forms of the compound.



3/093222 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Novel Form Of

N- (trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine

FIELD OF THE INVENTION

5

The present invention relates to a novel crystalline form of N- (trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and a process for preparing the same.

10 BACKGROUND OF THE INVENTION

N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine has therapeutic utility in depressing blood glucose levels in the management of Type 2 diabetes mellitus.

15

20

- N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine is disclosed in Japanese Patent Application No. 63-54321 (equivalent to EP-A-196222 and US 4,816,484). The Japanese application describes how the compound may be crystallized from aqueous methanol to yield crystals having a melting point of 129°C to 130° C. These crystals are referred as "B-type". These B-type crystals suffer from problems of instability, especially when subjected to mechanical grinding.
- J. Med. Chem. 32, 1436 (1989) discusses preparation of N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds which includes N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine.

US Patent Nos. 5,463,116 and 5,488,150 discloses preparation of novel crystalline form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine designated "H-type". This patent also discloses a method of treating form "B" crystals with appropriate solvent mixtures to obtain form "H" crystals and viceversa. The H-type crystals have an enhanced stability over B type crystals.

Yaowu Fenxi Zazhi 2001, 21, 342 discusses "S" form of nateglinide which is different from form "B" and form "H".

10 SUMMARY OF THE INVENTION

According to a first aspect of the invention there is provided a novel process for the production of novel crystalline form "C" of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine by reacting D-phenylalanine methylester HCl with *trans-4*-isopropylcyclohexane carboxylic acid in presence of propane phosphonic acid anhydride or LiOH-Al₂O₃ in halogenated hydrocarbon solvents such as dichloromethane, dichloroethane at a temperature between -10°C to 90° C followed by base hydrolysis.

Alternatively, the product can be obtained by reacting *trans-4*isopropylcyclohexane carbonyl chloride with D-phenylalanine methylester HCl
in halogenated hydrocarbon solvents such as dichloromethane, dichloroethane in
presence of base such as triethylamine, pyridine at a temperature between -10°C
to 90° C followed by base hydrolysis.

15

According to a still further aspect of the present invention, the new crystal from "C" of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine thus produced have at least one, and preferably all, of the following properties:

- (a) a melting point in the range of 126 °C to 132 °C;
 - (b) a powder X-ray diffraction pattern comprising characteristic peeks at 14.0, 17.8, 19.0, 20.2 and 21.2 ± 0.2 degrees measured at reflection angle 20;
- (c) an infrared absorption spectrum comprising absorption bands at with absorption bands in the region of 1742, 1648, 1599, 1540 and 1191 ± 2 cm⁻¹.

Yet another aspect of the invention includes a N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine Form C for use in the preparation of a medicament for treating Type 2 diabetes mellitus.

This invention also includes a pharmaceutical composition comprising a therapeutically effective amount of crystals of Form C N-(trans-4-isopropylcyclohexylcarbonyl)-D-Phenylalanine.

20

5

10

15

Another aspect of the invention, relates to a method for treating patients suffering from type 2 diabetes mellitus by administering a therapeutically effective amount of the pharmaceutical composition of Form C of N-(trans-4-isopropylcyclohexylcarbonyl)-D-Phenylalanine.

25

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

FIG. 1 shows a powder X-ray diffraction pattern of form C crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine;

FIG. 2 shows an infra red absorption spectrum of form C crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine;

DETAILED DECSRIPTION OF THE INVENTION

10

15

20

25

The process according to the inventors for preparing N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine form C comprises

- (a) suspending N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester in water or a water miscible solvent;
- (b) treating the suspension with a base;
- (c) addition of water followed by adjusting the pH to 1.0-4.0 using a mineral acid;
- (d) extracting using ethyl acetate;
- (e) concentrating the ethyl acetate extract;
- (f) addition of petroleum ether to the ethyl acetate concentrate; and
- (g) filtering and drying the precipitate obtained to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine form C.

The water miscible solvent in step (a) is selected from methanol, ethanol, isopropanol, or a mixture of these, preferably methanol. The base in step (b) is selected from potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide or a mixture of these preferably potassium carbonate.

The precipitate obtained in step (g) is suspended in water before filtration and drying to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine form C.

- N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester is prepared by:
 - reacting D-Phenylalanine methyl ester hydrochloride with trans-4-isopropylcyclohexane carboxylic acid in the halogenated hydrocarbons
- 10 filtering the reaction mixture;

15

- concentrating to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.

The first step in the above process for the preparation of N-(trans-4-

isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester is carried out in the presence of propane phosphonic acid anhydride, LiOH adsorbed in aluminium oxide or triethylamine.

An alternate method for producing N-(trans-4-

- 20 isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester comprises the steps of
 - reacting D-Phenylalanine methyl ester hydrochloride with trans-4isopropylcyclohexane carbonyl chloride in halogenated hydrocarbon solvents and in the presence of a base,
- 25 filtering the reaction mixture;
 - concentrating to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.

The halogenated hydrocarbon solvents are selected from dichloromethane or dichloroethane.

The base are selected from triethylamine or pyridine. The the reaction temperature is -10 ° to 90 ° C.

Embodiments of the invention are illustrated below by way of the following examples, not to be considered as limiting.

10

15

20

EXAMPLE 1

N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester:
D-Phenylalanine methyl ester hydrochloride (10g, 0.046 mol) was suspended in a solution of triethylamine (33 mL) in dichloromethane (50 mL); the mixture was cooled to 0-5 °C and trans-4-isopropylcyclohexane carboxylic acid (7.9 g, 0.046 mol) was added to the reaction mixture. A solution of Propane phosphonic acid anhydride (46.4 mL, 0.046 mol) in ethyl acetate was added dropwise over a period of 30 minutes, maintaining the temperature at 0-5 °C and stirred for 14 hours at ambient temperature. The reaction mixture was washed with 1.5 N HCl, 5% sodium bicarbonate solution and brine. The organic layer was concentrated to yield 12.5 g of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.

EXAMPLE 2

25 N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester:

D-Phenylalanine methyl ester hydrochloride (20g, 0.092 mol) was suspended in a solution of triethylamine (66 mL) in dichloroethane (100 mL) and the mixture was stirred for 1 h at room temperature. The organic layer was separated after washing with water and dried over anhydrous sodium sulphate. trans-4-Isopropylcyclohexane carboxylic acid (15.8 g, 0.092 mol) was added to the organic layer followed by LiOH-Al₂O₃ (5.5g of LiOH adsorbed on 40.5g Aluminum oxide) and refluxed for 24 hours. The reaction mixture was filtered over celite bed and washed with 1.5 N HCl, 5% sodium bicarbonate solution and brine. The organic layer was concentrated to yield 15.5 g of N-(trans-4-

EXAMPLE 3

10

15

N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester:

isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.

D-Phenylalanine methyl ester hydrochloride (26g, 0.12 mol) was suspended in a solution of triethylamine (85 mL) in dichloromethane (125 mL) and the mixture was cooled to 0-5 °C. A solution of trans-4-isopropylcyclohexane carbonyl chloride (25g, 0.13 mol) in dichloromethane (75 mL) was added dropwise over a period of 10 minutes, maintaining the temperature at 0-5° C and stirred for 12 hours at ambient temperature. The reaction mixture was washed with 1.5 N HCl, 5% sodium bicarbonate solution and brine. The organic layer was concentrated to yield 38g of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.

EXAMPLE 4

25

20

N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine:

To suspension of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester (38 g, 0.11 mol) in methanol (600 mL), a solution of potassium carbonate (80g, 0.57 mol) in water (400 mL) was added and the reaction mixture was stirred for 12 h at ambient temperature. Water (1500 mL) was added and pH was adjusted to 2.0 by adding 6N HCl. The mixture was extracted using ethyl acetate (3 x 400 mL) and the combined extract was washed with brine. The organic layer was concentrated to about 150 mL and pet. ether (300 mL) was added. The product was filtered and suspended in water (600 mL) and stirred for 12 hours at ambient temperature. The slurry

was filtered and dried to yield 35g of the title compound.

The compound showed a sharp melting point of 128 – 129 °C. X-ray diffraction pattern and infra red absorption spectrum of the final compound was recorded and identified as form C crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine.

We claim:

5

10

15

25

1. Crystalline N-(trans-4-isopropylcyclohexylcarbonyl)-D-Phenylalanine having at least one of the following properties:

- (a) a melting point in the range of 126° to 132 ° C:
- (b) a powder X-ray diffraction pattern comprising characteristic peeks at 14.0, 17.8, 19.0, 20.2 and 21.2 ± 0.2 degrees measured at reflection angle 2θ;
- (c) an infrared absorption spectrum comprising absorption bands at with absorption bands in the region of 1742, 1648, 1599, 1540 and 1191 + 2 cm⁻¹.
- 2. N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine Form C.
- 3. N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine Form C for use in the preparation of a medicament for treating Type 2 diabetes mellitus.
- 4. A process for preparing N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanine form C comprising the steps of:
 - (d) suspending N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanine methyl ester in water or a water miscible
 solvent;
 - (e) treating the suspension with a base;
 - (f) addition of water followed by adjusting the pH to 1.0-4.0 using a mineral acid;
 - (d) extracting using ethyl acetate;

- (e) concentrating the ethyl acetate extract:
- (f) addition of petroleum ether to the ethyl acetate concentrate;
- (g) filtering and drying the precipitate obtained to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine form C.

5

- 5. A process of claim 4 wherein the water miscible solvent in step (a) is selected from methanol, ethanol, isopropanol, or a mixture of these.
- 6. A process of claim 5 wherein the water miscible solvent in step (a) is methanol.
 - 7. A process of claim 4 wherein the base in step (b) is selected from potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide or a mixture of these.

15

20

- 8. A process of claim 7 wherein the base in step (b) is potassium carbonate.
- 9. A process of claim 4-8 wherein the precipitate obtained in step (g) is suspended in water before filtration and drying to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine form C.
- 10. A process of claim 4 wherein N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester of step (a) is prepared by:

25

- reacting D-Phenylalanine methyl ester hydrochloride with trans-4-isopropylcyclohexane carboxylic acid in the halogenated hydrocarbons

- filtering the reaction mixture;
- concentrating to get N-(trans-4isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.
- 5 11. A process of claim 10 wherein said halogenated hydrocarbon solvents are selected from dichloromethane or dichloroethane.
 - 12. A process of claim 10 wherein step (a) is carried out in the presence of propane phosphonic acid anhydride, LiOH adsorbed in aluminium oxide or triethylamine.
 - 13. A process of claim 4 wherein N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester of step (a) is prepared by:
 - reacting D-Phenylalanine methyl ester hydrochloride with trans-4-isopropylcyclohexane carbonyl chloride in halogenated hydrocarbon solvents and in the presence of a base,
 - filtering the reaction mixture;

10

15


- concentrating to get N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine methyl ester.
- 14. A process of claim 13 wherein said halogenated hydrocarbon solvents are selected from dichloromethane or dichloroethane.
- 25 15. A process of claim 13 wherein said base are selected from triethylamine or pyridine.

16. A process of claim 10 or 13 wherein the reaction temperature is $-10 \circ to 90 \circ C$.

17. A pharmaceutical composition comprising a therapeutically


effective amount of crystals of Form C N-(trans-4isopropylcyclohexylcarbonyl)-D-Phenylalanine according to claim 1.

FIG 1



Intensity (a.u.)

FIG 2



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IN02/00114

A. CLASSIFICATION OF SUBJECT MATTER Int Cl. ** CO7C 233/63; A61K 31/198 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED B. FIELDS SEARCHED Documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (same of data base and, where practicable, search terms used) STN: Chermical Abstracts, based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) I October 1986 See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-{Cyclohexylcarbonyl}-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 No. 7, pp 1436-41. X See table II, compound 13 I-17 LUS 5,463,116 A (Surnikawa et al.) 31 October 1995 A Whole document "E" entire application or patent but published on or astre the international filing date or priority date and the published of sed another visition or other sense." """ document efficiting the general state of the art which may throw doubts on priority claim of the content of paticular relevance, the claimed invention cannot be considered to rother means." """ document published and another visition or other sense." """ document published prior to the international filing date to repriority date achieved to rother means." """ document published prior to the international filing date to make the published on or astre the international filing date to priority date considered to rother means. """ document published prior to the international filing date to make the published prior to the international filing date to make the published prior to the in	r 			1 C1/11/02/00114						
According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Chemical Abstracts; based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycernic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp. 1436-41. X See table II, compound 13 US 5,463,116 A (Surnikawa et al.) 31 October 1995 A Whole document defining the general state of the art which is not considered to the of particular which is not considered to the of particular cannot be considered to the or particular cannot be considered to considered to the or particular cannot decrease the claimed invention cannot be considered to word cannot be considered to involve an inventive step when the document is combined when the many through the publication or other means """ document effering to a not all disclosure, use, exhibition or other means """ document effering to a road disclosure, use, exhibition or other means """ document effering to a road disclosure, use, exhibition or other means """ document effering to a road disclosu	Α.	CLASSIFICATION OF SUBJECT MATTER								
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Chemical Abstracts; based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 See example 31, (m.p.). (& US 4,316,484 A) Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycernic Agents. 2."; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp. 1436-41. X See table II, compound 13 US 5,463,116 A (Sumikawa et al.) 31 October 1995 A Whole document defining the general state of the art which is not considered to be of particular arther the international filing date on priority claim and the fining the general state of the art which is not considered to be of particular or effects application of the international filing date on priority date claimed in the publication of or other means "E" document efferting to a not all disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document efferting to a roal disclosure, use, exhibition or other means "C" document effer	Int. Cl. 7:	C07C 233/63; A61K 31/198								
Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Chemical Abstracts; based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylearbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. See table II, compound 13 US 5,463,116 A (Surnikawa et al.) 31 October 1995 A Whole document "I." Special categories of cited documents, and comment defining the general state of the art which is not considered to be of particular relevance defining the general state of the art which is not considered to the official state of the art which is not considered to the oral transmission lifting date "I." document defining the general state of the art which is not considered to the cited to understand the principle or after the international filling date or priority date and not in conflict with the application but cited to understand the principle or the cited to establish the published prior to the international filling date or priority date and not in conflict with the application but cited to understand the principle or the cited to establish the published prior to the international filling date or priority date claimed of the extent published prior to the international filling date or priority date claimed or priority date (as published prior to the international search expectation or other means decument published prior to the international search ex	According to International Patent Classification (IPC) or to both national classification and IPC									
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Chemical Abstracts; based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 X See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylearbonyl)-D-phenylalanines and Related Compounds, A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. X See table II, compound 13 1-17 US 5,463,116 A (Sumikawa et al.) 31 October 1995 A Whole document ** Special categories of cited documents are listed in the continuation of Box C ** Special categories of cited documents such considered to be of particular relevance the claimed investion cannot be considered novel or cannot be considered to impove an inventive step when the document is taken alone and no in conflict with the application or other means """ ** Special categories of cited documents are listed in the continuation of Box C ** Special categories of cited documents which may throw doubts on priority claims and no in conflict with the application but cited to understand the principle or heavy underlying the invention cannot be considered novel or cannot be considered to impove an inventive step when the document is taken alone and no in conflict with the application part patient or about the supplication patient in the art occument of particular relevance, the claimed investion cannot be considered to work an inventive step when the document is taken alone and no in conflict with the application patient in the art occument of particular relevance, the claimed investion cannot be considered to work as in wardie step when the docume	B. FIELDS SEARCHED									
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Chemical Abstracts; based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 X Sce example 31, (m.p.). (& US 4,316,484 A) Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 No. 7, pp 1436-41. X See table II, compound 13 I-17 IV Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance: "B" earlier application or patent but published on or after the international filing date or priority date visition to orther means to example 31, or which is cited to stablish the publication date of mother citation or other special reason (as specified) "C" document which may throw doubts on priority claimed priority of the international filing date or priority date claimed or which is cited to stablish the publication of the international filing date or priority date claimed or which is cited to stablish the publication of the many throw doubts on priority date claimed or which is cited to stablish the publication of the office or the priority date claimed or which is cited to stablish the publication of the international filing date or priority date claimed or which is cited to stablish the publication of the international filing date or priority date claimed or which is cited to stablish the publication of the international filing date or priority date claimed or which is cited to stablish the publication of the international filing date or priority date claimed or which is cited to stablish the publication of the international filing date or priority date claimed or which is cited to	Minimum documentation searched (classification system followed by classification symbols)									
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN: Chemical Abstracts; based on the compound of the invention in the claims C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylearbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 No. 7, pp 1436-41. X See table II, compound 13 I-17 IX Further documents are listed in the continuation of Box C X See patent family annex *Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance; and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered nowel or emnot be considered nowel or emnot be considered nowel or such document of particular relevance; the claimed invention cannot be considered or or when the document is taken alone document of particular relevance; the claimed invention cannot be considered or or other reasons """ document referring to an oral disclosure, use, exhibition or other reasons """ document or particular relevance; the claimed invention cannot be considered nowel or emnot be con	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched									
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. See table II, compound 13 US 5,463,116 A (Surnikawa et al.) 31 October 1995 A Whole document Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance earlier application of patent but published on or after the international filing date creasing (as specified) "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of mother citation or other resear. "B" document which may throw doubts on priority claim(s) or which is cited to stablish the publication of the international filing date to relevance exhibition or other means. "B" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an invention cannot be considered novel or cannot b	December and a property of the design of the second of the									
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 196 222 B1 (AJINOMOTO CO., INC.) 1 October 1986 X See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2", Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. X See table II, compound 13 I-17 X Further documents are listed in the continuation of Box C X Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance." "E" earlier application or patent but published on or after the international filing date or priority claim(s) or which is cited to establish the publication date of mother citation or other special reason (as specified) "C" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date or priority claim(s) or which is cited to establish the publication date of mother citation or other special reason (as specified) "C" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date or priority claim to the continuation of Box C X See patent family annex "T" later document published after the international filing date or priority claim and not in conflict with the application but clied to undestrable the principle or theory underlying the invention beconsidered to involve an inventive step when the document is taken alone document problemed prior to the international filing date but later flam the priority date claimed Date of the actual completion of the international search 5 September 2002 Name and mailing address of the ISNAU Authorised officer G. D. HEARDER				rch terms used)						
Special categories of cited documents are listed in the continuation of Box C See patent family amnex	C.	DOCUMENTS CONSIDERED TO BE RELEVANT	_							
See example 31, (m.p.). (& US 4,816,484 A) Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. X See table II, compound 13 1-17 US 5,463,116 A (Sumikawa et al.) 31 October 1995	Category*	Citation of document, with indication, where appro-	priate, of the relevant passages	•						
Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. X See table II, compound 13 US 5,463,116 A (Sumikawa et al.) 31 October 1995 A Whole document * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published into the international filing date of the actual completion of the international filing date on the document is taken alone document published ripor to the international filing date or priority date claimed on the document is taken alone document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date or priority date claimed on the document is taken alone "Y" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 5 September 2002 Name and mailing address of the ISA/AU Authorised officer A Web a decument published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to involve an inventive step when the document is taken alone "Y" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date or priority date claimed invention cannot be considered to movel an inventive step when the document i			October 1986							
Shinkai H et al.: "N-(Cyclohexylcarbonyl)-D-phenylalanines and Related Compounds. A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. X See table II, compound 13 I-17 I See table II, compound 13 I -17 X Further documents are listed in the continuation of Box C Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" erlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document treferring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search September 2002 Name and mailing address of the ISA/AU Authorised officer A We document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document of particular relevance, the claimed invention cannot be considered in onlove an inventive step when the document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document of particular relevance, the claimed with one or more other such document, such combination being obvious to a person skilled in the art occument is particular relevance, the claimed invention cannot be considered to involve an in	X			1-17						
A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. See table II, compound 13 I-17 US 5,463,116 A (Sumikawa et al.) 31 October 1995 Whole document I-17 Example of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. See table II, compound 13 I-17 I US 5,463,116 A (Sumikawa et al.) 31 October 1995 Whole document I-17 Example of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41. See table II, compound 13 I-17 I I US 5,463,116 A (Sumikawa et al.) 31 October 1995 I I-17 I I I I I I I I I I I I I I I I I I		(,								
Whole document X Further documents are listed in the continuation of Box C Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document referring to an oral disclosure, use, exhibition or other means "P" document referring to an oral disclosure, use, exhibition or other means "D" document referring to an oral disclosure of the actual completion of the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered to involve an inventive step when the document is exhibition or other means "A" document referring to an oral disclosure, use, exhibition or other means "D" document referring to an oral disclosure, use, exhibition or other means "D" document referring to the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention and to time conflict with the application but cited to understand the principle or theory underlying the invention and to inconflict with the application but cited to understand the principle or theory underlying the invention and to inconflict with the application but cited to understand the principle or theory underlying the invention of the considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive ste	x	A New Class of Oral Hypoglycemic Agents. 2"; Journal of Medicinal Chemistry, 1989, Vol. 32 NO. 7, pp 1436-41.								
* Special categories of cited documents: "A" Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance after the international filing date "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date to move or more other such document; such combination being obvious to a person skilled in the art document member of the same patent family Date of the actual completion of the international search 5 September 2002 Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: ptd@ipaustralia.gov.au	7.			1						
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published and in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family "E" document referring to an oral disclosure, use, exhibition or other means document referring to an oral disclosure, use, exhibition or other means document published and to in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone "Y" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure, use, exhibition or other means "B" document referring to an oral disclosure,	A									
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search September 2002 Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Iater document published after the international filing the art which is cited to be of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document of particular relevance; the claimed inven	X F	urther documents are listed in the continuation o	of Box C X See pate	ent family annex						
claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search September 2002 Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report 17 SEP 2002 Authorised officer G. D. HEARDER	"A" document defining the general state of the art which is not considered to be of particular relevance or theory underlying the invention "E" earlier application or patent but published on or after the international filing date "X" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of patent but cited to understand the principle or theory underlying the invention "X" document of patent but cited to understand the principle or theory underlying the invention "Considered novel or cannot be considered to involve an inventive step									
"O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 5 September 2002 Name and mailing address of the ISA/AU Authorised officer AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au "&" document member of the same patent family	claim(s) or which is cited to establish the considered to involve an inventive step when the document is combined									
"P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 5 September 2002 Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Date of mailing of the international search report 1 7 SEP 2002 Authorised officer J G. D. HEARDER	"O" document referring to an oral disclosure, use, "&" document member of the same patent family									
5 September 2002 Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Authorised officer G. D. HEARDER	"P" document published prior to the international filing									
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Authorised officer G. D. HEARDER	4.0.000									
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au G. D. HEARDER	<u> </u>									
PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au G. D. HEARDER										
D-man address. per@ipadsuana.gov.ad	PO BOX 200, W	ODEN ACT 2606, AUSTRALIA	•							
		ott@ipaustralia.gov.au		,						

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IN02/00114

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to								
ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.						
·	Chemical Abstracts 136:159110; Li G et al.: "A new crystal structure in nateglinide							
Α	found by X-ray powder diffraction"; Yaowu Fenxi Zazhi (2001), 21(5), 342-344 Abstract	1-17						
Α	Ausu act	1-17						
	·							
_								
•								
	•							

INTERNATIONAL SEARCH REPORT

International application No.

Information on patent family members

PCT/IN02/00114

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

	nt Document Cited in Search Report			Pate	ent Family Member		
EP	196222	US	4816484	JР	63054321		
US	5463116	BR	1100807	CA	2114678	EP	526171
		LU	90843	LU	90846	US	5488150
		JР	5208943				
							END OF ANNEX